Inflammatory response to recombinant human bone morphogenetic protein-2 use in the treatment of a proximal humeral fracture: A case report

Journal of Shoulder and Elbow Surgery

Volumn 21, Issue 1, 2012, Pages

  Julka, Abhishek ^a   Shah, Apurva S ^b   Miller, Bruce S ^a  

^a UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN SPONGE; CORTICOSTEROID; PREDNISONE; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2;

ADULT; ANTICOAGULATION; ARM SWELLING; ARTICLE; CASE REPORT; EDEMA; ERYTHEMA; FEMALE; FRACTURE NONUNION; HETEROTOPIC OSSIFICATION; HUMAN; HUMERUS FRACTURE; OPEN REDUCTION; OSTEOSYNTHESIS; PAIN; PERIOPERATIVE PERIOD; PHLEBOGRAPHY; PRIORITY JOURNAL; RADIOGRAPHY; RANGE OF MOTION; SECONDARY AXILLARY VEIN COMPRESSION; SOFT TISSUE EDEMA; UPPER EXTREMITY DEEP VEIN THROMBOSIS; VASCULAR DISEASE;

BONE MORPHOGENETIC PROTEIN 2; FEMALE; FOLLOW-UP STUDIES; FRACTURE FIXATION, INTERNAL; FRACTURE HEALING; HUMANS; INFLAMMATION; MIDDLE AGED; RECOMBINANT PROTEINS; SHOULDER FRACTURES; TOMOGRAPHY, X-RAY COMPUTED; TRANSFORMING GROWTH FACTOR BETA;

EID: 83555165061     PISSN: 10582746     EISSN: 15326500     Source Type: Journal    
DOI: 10.1016/j.jse.2011.06.006     Document Type: Article

References (19)

1. Axelrad T.W., Steen B., Lowenberg D.W., Creevy W.R., Einhorn T.A. Heterotopic ossification after the use of commercially available recombinant human bone morphogenetic proteins in four patients. J Bone Joint Surg Br 2008, 90:1617-1622. 10.1302/0301-620X.90B12.20975.
2. Brower R.S., Vickroy N.M. A case of psoas ossification from the use of BMP-2 for posterolateral fusion at L4-L5. Spine 2008, 33:E653-E655. 10.1097/BRS.0b013e31817c4f1c.
3. Burkus J.K., Gornet M.F., Dickman C.A., Zdeblick T.A. Anterior lumbar interbody fusion using rhBMP-2 with tapered interbody cages. J Spinal Disord Tech 2002, 15:337-349.
4. Cahill K.S., Chi J.H., Day A., Claus E.B. Prevalence, complications, and hospital charges associated with use of bone-morphogenetic proteins in spinal fusion procedures. JAMA 2009, 302:58-66. 10.1001/jama.2009.956.
5. Chen N.F., Smith Z.A., Stiner E., Armin S., Sheikh H., Khoo L.T. Symptomatic ectopic bone formation after off-label use of recombinant human bone morphogenetic protein-2 in transforaminal lumbar interbody fusion. J Neurosurg Spine 2010, 12:40-46. 10.3171/2009.4.SPINE0876.
6. Deutsch H. High-dose bone morphogenetic protein-induced ectopic abdomen bone growth. Spine J 2010, 10:e1-e4. 10.1016/j.spinee.2009.10.016.
7. Ebara S., Nakayama K. Mechanism for the action of bone morphogenetic proteins and regulation of their activity. Spine 2002, 27(16S):S10-S15.
8. Einhorn T.A., Majeska R.J., Mohaideen A., Kagel E.M., Bouxsein M.L., Turek T.J., et al. A single percutaneous injection of recombinant human bone morphogenetic protein-2 accelerates fracture repair. J Bone Joint Surg Am 2003, 85:1425-1435.
9. Govender S., Csimma C., Genant H.K., Valentin-Opran A., Amit Y., Arbel R., et al. BMP-2 Evaluation in surgery for tibial trauma (BESTT) study group. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am 2002, 84:2123-2134.
10. Joseph V., Rampersaud Y.R. Heterotopic bone formation with the use of rhBMP2 in posterior minimal access interbody fusion: a CT analysis. Spine 2007, 32:2885-2890. 10.1097/BRS.0b013e31815b7596.
11. MacDonald K.M., Swanstrom M.M., McCarthy J.J., Nemeth B.A., Guliani T.A., Noonan K.J. Exaggerated inflammatory response after use of recombinant bone morphogenetic protein in recurrent unicameral bone cysts. J Pediatr Orthop 2010, 30:199-205. 10.1097/BPO.0b013e3181cec35b.
12. Schultz DG. P000058 letter of approval. 7-2-2002. Department of Health and Human Services, Center for Devices and Radiological Health. Accessed: Aug 18, 2010. http://www.accessdata.fda.gov/cdrh_docs/pdf/P000058a.pdf.
13. Schultz DG. P000058 letter of approval. 4-30-2004. Department of Health and Human Services, Center for Devices and Radiological Health. Accessed: Aug 18, 2010. http://www.accessdata.fda.gov/cdrh_docs/pdf/p000054a.pdf.
14. Sciadini M.F., Johnson K.D. Evaluation of recombinant human bone morphogenetic protein-2 as a bone-graft substitute in a canine segmental defect model. J Orthop Res 2000, 18:289-302.
15. Haidar Z., Hamdy R., Tabrizian M. Delivery of recombinant bone morphogenetic proteins for bone regeneration and repair. Part B: delivery systems for BMPs in orthopaedic and craniofacial tissue engineering. Biotechnol Lett 2009, 31:1825-1835. 10.1007/s10529-009-0100-8.
16. Shields L.B., Raque G.H., Glassman S.D., Campbell M., Vitaz T., Harpring J., et al. Adverse effects associated with high-dose recombinant human bone morphogenetic protein-2 use in anterior cervical spine fusion. Spine 2006, 31:542-547. 10.1097/01.brs.0000201424.27509.72.
17. Smucker J.D., Rhee J.M., Singh K., Yoon S.T., Heller J.G. Increased swelling complications associated with off-label usage of rhBMP-2 in the anterior cervical spine. Spine 2006, 31:2813-2819. 10.1097/01.brs.0000245863.52371.c2.
18. Tsuji K., Bandyopadhyay A., Harfe B.D., Cox K., Kakar S., Gerstenfeld L., et al. BMP2 activity, although dispensable for bone formation, is required for the initiation of fracture healing. Nat Genet 2006, 38:1424-1429. 10.1038/ng1916.
19. Valdes M., Thakur N., Namdari S., Ciombor D., Palumbo M. Recombinant bone morphogenic protein-2 in orthopaedic surgery: a review. Arch Orthop Trauma Surg 2009, 129:1651-1657. 10.1007/s00402-009-0850-8.